dc.contributor.author |
Gambato, Martina |
dc.contributor.author |
Caro-Pérez, Noelia |
dc.contributor.author |
González, Patricia |
dc.contributor.author |
Cañete Hidalgo, Nuria |
dc.contributor.author |
Mariño, Zoe |
dc.contributor.author |
Lens, Sabela |
dc.contributor.author |
Bonacci, Martín |
dc.contributor.author |
Bartres, Concepció |
dc.contributor.author |
Sánchez-Tapias, José María |
dc.contributor.author |
Carrión Rodríguez, José Antonio |
dc.contributor.author |
Forns, Xavier |
dc.contributor.author |
Juan, Manuel |
dc.contributor.author |
Pérez-Del-Pulgar, Sofía |
dc.contributor.author |
Londoño, María Carlota |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2016 |
dc.identifier |
https://ddd.uab.cat/record/249578 |
dc.identifier |
urn:10.1371/journal.pone.0166631 |
dc.identifier |
urn:oai:ddd.uab.cat:249578 |
dc.identifier |
urn:pmid:27861593 |
dc.identifier |
urn:scopus_id:84995961602 |
dc.identifier |
urn:articleid:19326203v11n11e0166631 |
dc.identifier |
urn:pmc-uid:5115763 |
dc.identifier |
urn:pmcid:PMC5115763 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:5115763 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Ministerio de Economía y Competitividad PI13-00155 |
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca 2014-SGR605 |
dc.relation |
PloS one ; Vol. 11 Núm. 11 (november 2016), p. e0166631 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.title |
Neutrophil and monocyte function in patients with chronic hepatitis c undergoing antiviral therapy with regimens containing protease inhibitors with and without interferon |
dc.type |
Article |
dc.description.abstract |
Real-life data showed an increased incidence of bacterial infections in patients with advanced liver disease receiving a protease inhibitor (PI)-containing antiviral regimen against hepatitis C (HCV). However, the causes of this event are unknown. We hypothesized that PIs might impair innate immune responses through the inhibition of proteases participating in the anti-bacterial functions of neutrophils and monocytes. The aims of the study were to assess phagocytic and oxidative burst capacity in neutrophils and monocytes obtained from patients receiving a PI containing-antiviral regimen, and to determine cytokine secretion after neutrophil stimulation with flagellin. Forty patients with chronic HCV (80% with cirrhosis) were enrolled in the study, 28 received triple therapy (Group A) with pegylated-interferon and ribavirin for 4 weeks followed by the addition of a PI (telaprevir, boceprevir or simeprevir), and 12 patients received an interferon-free regimen (Group B) with simeprevir and sofosbuvir. Phagocytosis and oxidative burst capacity were analyzed by flow cytometry at baseline, week 4, and week 8 of therapy. In neutrophils from Group A patients, oxidative burst rate and oxidative enzymatic activity per cell significantly decreased throughout the study period (p = 0.014 and p = 0.010, respectively). Pairwise comparisons showed a decrease between baseline and week 4 and 8 of therapy. No differences were observed after the introduction of the PI. The oxidative enzymatic activity per cell in monocytes significantly decrease during the study period (p = 0.042) due to a decrease from baseline to week 8 of therapy (p = 0.037) in patients from Group A. None of these findings were observed in Group B patients. Cytokine secretion did not significantly change during the study in both groups. In conclusion, our data suggest that the use interferon (rather than the PI) has a deleterious effect on neutrophil and monocyte phagocytic and oxidative burst capacity in this cohort of patients with HCVrelated advanced liver fibrosis. |